Carole Ho is our Chief Medical Officer and Head of Development. At Denali, Carole has built an integrated Development organization that is responsible for advancing therapeutic candidates from pre-IND enabling studies through Phase 1 to Phase 3 clinical trials. Under Carole’s leadership, her team has delivered on Denali’s biomarker driven development strategy to enable early target and pathway engagement in the clinic for therapeutics in development for Parkinson’s disease, Alzheimer's disease, and ALS.
Carole previously served as Vice President of Genentech Early Clinical Development and was responsible for delivery of pivotal trial-ready drug candidates in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8-year tenure at Genentech, Carole held roles with leadership responsibility across multiple early- and late-stage clinical programs including Rituxan® for Wegener’s granulomatosis and microscopic polyangiitis, ocrelizumab for Multiple Sclerosis, lampalizumab for dry AMD, and crenezumab for Alzheimer’s Disease. At Genentech, in collaboration with Banner Health, Carole's team led the initiation of the world's first prevention trial in Alzheimer's disease in participants at risk for dementia due to a genetic mutation.
Carole completed her residency in Neurology at Harvard Medical School at the Massachusetts General Hospital / Brigham and Women’s Hospital, where she also served as Chief Resident. She obtained her M.D. from Cornell University and S.B. in Biochemical Sciences from Harvard College. Prior to her Industry career, Carole was on Faculty in the Department of Neurology at Stanford University. Carole currently serves on the Board of Directors of Beam Therapeutics.
What is Carole Ho's net worth?
The estimated net worth of Carole Ho is at least $3.54 million as of February 13th, 2024. Dr. Ho owns 145,010 shares of Denali Therapeutics stock worth more than $3,541,144 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Ho may own. Additionally, Dr. Ho receives a salary of $802,290.00 as Insider at Denali Therapeutics. Learn More about Carole Ho's net worth.
How old is Carole Ho?
Dr. Ho is currently 51 years old. There are 3 older executives and no younger executives at Denali Therapeutics. The oldest executive at Denali Therapeutics is Dr. Marc Tessier-Lavigne Ph.D., Co-Founder & Independent Director, who is 64 years old. Learn More on Carole Ho's age.
What is Carole Ho's salary?
As the Insider of Denali Therapeutics Inc., Dr. Ho earns $802,290.00 per year. The highest earning executive at Denali Therapeutics is Dr. Ryan J. Watts Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,150,000.00 per year. Learn More on Carole Ho's salary.
How do I contact Carole Ho?
Has Carole Ho been buying or selling shares of Denali Therapeutics?
Carole Ho has not been actively trading shares of Denali Therapeutics within the last three months. Most recently, Carole Ho sold 2,784 shares of the business's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a transaction totalling $48,135.36. Following the completion of the sale, the insider now directly owns 145,010 shares of the company's stock, valued at $2,507,222.90. Learn More on Carole Ho's trading history.
Who are Denali Therapeutics' active insiders?
Are insiders buying or selling shares of Denali Therapeutics?
In the last twelve months, insiders at the sold shares 20 times. They sold a total of 276,160 shares worth more than $6,312,378.82. The most recent insider tranaction occured on November, 7th when insider Alexander O Schuth sold 15,558 shares worth more than $465,339.78. Insiders at Denali Therapeutics own 7.9% of the company.
Learn More about insider trades at Denali Therapeutics. Information on this page was last updated on 11/7/2024.
